Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Cash from Operations (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Cash from Operations for 6 consecutive years, with 5545000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 3.63% to 5545000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 22184000.0 through Dec 2025, down 7.23% year-over-year, with the annual reading at 22184000.0 for FY2025, 7.23% down from the prior year.
  • Cash from Operations hit 5545000.0 in Q4 2025 for Insight Molecular Diagnostics, down from 4502000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 3769000.0 in Q3 2023 to a low of 13277000.0 in Q1 2022.
  • Historically, Cash from Operations has averaged 7385350.0 across 5 years, with a median of 6555500.0 in 2023.
  • Biggest five-year swings in Cash from Operations: plummeted 82.9% in 2021 and later surged 66.93% in 2023.
  • Year by year, Cash from Operations stood at 7065000.0 in 2021, then plummeted by 36.56% to 9648000.0 in 2022, then soared by 54.15% to 4424000.0 in 2023, then decreased by 20.95% to 5351000.0 in 2024, then decreased by 3.63% to 5545000.0 in 2025.
  • Business Quant data shows Cash from Operations for IMDX at 5545000.0 in Q4 2025, 4502000.0 in Q3 2025, and 6279000.0 in Q2 2025.